The P2Y 12 receptor antagonist ticagrelor has been shown to be clinically superior to clopidogrel. Although the underlying mechanisms remain elusive, ticagrelor may exert off-target effects through adenosine-related mechanisms. We aimed to investigate whether ticagrelor reduces myocardial injury to a greater extent than clopidogrel after myocardial infarction (MI) at a similar level of platelet inhibition and to determine the underlying mechanisms.
F or more than a decade dual-antiplatelet therapy with aspirin (cyclooxygenase inhibitor) and clopidogrel (P2Y 12 receptor antagonist and a second-generation thienopyridine) has remained the cornerstone of treatment for patients with acute coronary syndrome (ACS). 1 Despite the benefits associated with clopidogrel therapy in these high-risk patients, laboratory and clinical experience have led to the identification of several clopidogrel limitations, including delayed onset of action and high interindividual variability, 2 underscoring the need for improved antiplatelet treatment strategies. In this regard, the more recent oral P2Y 12 -receptor antagonist prasugrel (a third-generation thienopyridine) and ticagrelor (a cyclopentyltriazolo-pyrimidine) have been shown to overcome many of the pharmacodynamic limitations associated with clopidogrel treatment, eventually improving outcomes in patients with ACS. 3, 4 Ticagrelor, unlike the thienopyridines, blocks the platelet P2Y 12 receptor in a reversible manner and displays pharmacological properties that translate into a faster onset of action in comparison to clopidogrel. 5 Several clinical studies have supported the safety, tolerability, and efficacy of ticagrelor in the setting of stable coronary disease and acute myocardial infarction (MI), and a greater absolute benefit over clopidogrel, as well. 6, 7 In the PLATO trial (Platelet Inhibition and Patient Outcomes), 3 ticagrelor demonstrated superiority in comparison with clopidogrel in patients with ACS, reducing cardiovascular morbidity 8 and mortality 9 with a similar incidence of coronary artery bypass grafting-related major bleeding, although the rate of non-coronary artery bypass grafting-related major bleeding was higher with ticagrelor. In addition, a post hoc analysis of the PLATO trial has suggested that ticagrelor reduces sudden death in comparison with clopidogrel 9 and has also been shown to lower the risk of recurrent ischemic events, including cardiovascular and coronary heart disease death, in diabetic patients with a history of MI. 10 Faster onset of action and more potent and reversible receptor binding are possible explanations for the increased superiority of ticagrelor over clopidogrel. Yet, ticagrelor has been shown, beyond its antiplatelet activity, to exert off-target effects likely contributing to the clinical benefit. Specifically, ticagrelor inhibits the equilibrative nucleoside transporter-1 (ENT-1) that is implicated in the cellular uptake of adenosine. Adenosine is locally formed at sites of ischemic tissue damage and exerts a wide range of cardiovascular benefits (eg, vasodilation, inhibition of platelet aggregation, and leukocyte adherence to the vessel wall). 11, 12 Hence, ticagrelor inhibition of ENT-1 and consequent local adenosine increase may lead to additional protective effects. 13 So far, several antiplatelet agents have been shown to exert cardioprotective effects. As such, in patients who have ST-segment-elevation myocardial infarction (STEMI), intracoronary administration of abciximab has been shown to reduce infarct size assessed by cardiac MRI (CMR) 14 and clopidogrel has been shown to reduce cardiac enzyme release. 15 Ticagrelor, has been demonstrated in a rat model of transient coronary occlusion to diminish the size of infarction, an effect not observed on clopidogrel treatment. 16 In the present study, we aimed to compare the efficacy of ticagrelor and clopidogrel in protecting the heart against tissue injury and dysfunction in a swine model of closed-chest MI by using 3T-CMR.
MethODs
Expanded Materials and Methods are available in the onlineonly Data Supplement.
The study protocol was approved by the institutional ethics committee (CSIC-ICCC) and all animal procedures were performed in strict accordance with the guidelines from Directive 2010/63/EU or the National Institutes of Health (NIH) guidelines (NIH Publication No. 85-23, revised 1996).
experimental Design
Online-only Data Supplement Figure I includes a diagram depicting the experimental protocol. In brief, pigs were allocated to randomly and blindly receive the following before MI induction: (1) placebo-control (n=9); (2) loading dose of clopidogrel (600 mg; n=8); (3) a loading dose of ticagrelor (180 mg; n=8); and (4) a loading dose of ticagrelor followed by an intravenous infusion of an adenosine A1/A2-receptor antagonist {8-(p-sulfophenyl)theophylline [8SPT]; 4 mg/kg; n=7}. 17 These starting dosages of clopidogrel and ticagrelor were selected because they achieved similar inhibition of ADP-induced aggregation. The timing and dose of administration, 2 hours for ticagrelor and 4 hours for clopidogrel before clinical Perspective What is new?
• We show that ticagrelor reduces cardiac damage post-myocardial infarction (necrosis and edema) to a greater extent than clopidogrel by an adenosineinduced organ-protective response. • We propose a possible molecular signaling pathway by which ticagrelor might reduce myocardial edema.
What are the clinical implications?
• Our studies provide reliable and mechanistic demonstration (use of a preclinical animal model of closed-chest myocardial infarction in combination with 3T-cardiac MRI, pathological and molecular analysis) that the benefits of ticagrelor exceed the platelet-inhibition effects. • Ticagrelor cardioprotective effects extend beyond its platelet function inhibition, helping to explain the beneficial effects seen clinically in the PLATO trial (Platelet Inhibition and Patient Outcomes).
MI induction, was based on a crossover dose-finding pilot study, the details of which are provided in the online-only Data Supplement Methods. Throughout the 24 hours post-MI, the animals received the corresponding maintenance doses of the antiplatelet agents. As such, ticagrelor was administered twice daily (90 mg every 12 hours) and clopidogrel-treated animals received a single 75-mg maintenance dose. Then animals were anesthetized and brought to the CMR facility. Thereafter, animals were euthanized, and histopathologic analysis of infarct size was assessed and myocardial samples were collected for molecular analysis.
study end Points
The cardiovascular end points of the following study included the assessment of the beneficial effects of ticagrelor over clopidogrel on the infarcted cardiac tissue (infarct size and edema formation) and cardiac performance (contractility) acutely post-MI.
experimental induction of Mi
MI was experimentally induced by a 1-hour total balloon occlusion of the mid-left anterior descending coronary artery as previously described. 18 Left ventricular ejection fraction (LVEF) was assessed by echocardiography before inducing ischemia (prior-MI) and on reperfusion (post-MI) to monitor the degree of MI induction.
3t-cMr acquisition and Data analysis
The studies were performed on a 3.0T-CMR system (Achieva, Philips) by operators blinded to the study medication as previously reported. 18 Details of the technical parameters for all CMR sequences are provided in online-only Data Supplement  Table I , and the details of the protocol analysis have been detailed elsewhere. 18 
Platelet Function assay and coagulation Function and Dynamics
The present study aimed to evaluate whether ticagrelor in comparison with clopidogrel provides cardioprotective effects when dosed to equal inhibition of ADP-induced platelet aggregation. To define the doses to use, we conducted a crossover dose-finding pilot study in 4 naïve animals. The methodology and results of this pilot study are detailed in the online-only Data Supplement Methods. Based on these results (onlineonly Data Supplement Figure II ), 180 mg of ticagrelor and 600 mg of clopidogrel were selected, which, in turn, concur with the dosages used in the PLATO trial. 3 Ticagrelor was administered 2 hours and clopidogrel 4 hours before experimental MI. Conventional coagulation function parameters and thromboelastometric coagulation analysis were also evaluated in this pilot study to discard any potential effect on blood coagulation (online-only Data Supplement Table II ). In the main study, platelet function was additionally monitored before treatment (baseline), prior-MI induction, post-MI induction, and at 24 hours by light transmittance aggregometry and results were reported as inhibition of platelet aggregation. Blood count (System 9000) and bleeding time were also determined by using the Simplate device in the ear skin and recorded as time until bleeding cessation.
analyses of Markers of edema in the Myocardium
We performed molecular analysis of 2 proteins reported to be involved in edema formation. As such, we assessed aquaporin-4, 19 a protein with a key role in intracellular edema formation, 20 and AMP-activated protein kinase (AMPK), 21 which, besides sensing cardiac energy metabolism, 22 has been shown to protect against edema formation by preserving vascular permeability. 21 To that end, tissue samples, obtained from the ischemic and remote myocardium, were processed for the analysis of: (1) mRNA and protein levels of aquaporin-4; and (2) AMPK, AMPK phosphorylated at Thr 172 (P-AMPK), and downstream effectors endothelial nitric oxide synthase (eNOS) phosphorylated at Ser 1177 (P-eNOS) and CD36 protein levels. In addition, aquaporin-4 expression was analyzed in different cardiac cell types in vitro (porcine aortic endothelial cells, porcine fibroblasts, and HL-1 cardiomyocytes).
Myocardial enzymes and cyclooxygenase-2 activity
Cardiac troponin-I was evaluated in all swine 24 hours post-MI using a high-sensitivity Pig Elisa kit. Previous work in rodents 16 has reported the ability of ticagrelor to induce cardiac cyclooxygenase-2 (Cox2) activation. We further assessed this hypothesis in a more complex preclinical model (swine) and determined whether it was an adenosine-mediated effect. Accordingly, we evaluated myocardial Cox2 activity and prostaglandin F1α release as previously described. 16 
statistical analysis
After assessment for normal distribution of the data (ie, Shapiro-Wilk normality test), the pilot study was evaluated by repeated-measures analysis of variance and results reported as mean±standard error of the mean, whereas the main study by nonparametric statistical analyses and results are reported as medians and interquartile range. Comparisons between groups at end points were performed by Kruskal-Wallis and Mann-Whitney followed by post hoc Bonferroni correction. A linear mixed model was applied for analysis of repeated measurements across time. All statistical tests conducted were 2-sided. Statistical significance was considered P<0.05 and we used the Statview and R packages 
effect of clopidogrel and ticagrelor on Platelet Function
Platelet activation at baseline was comparable among all animals (ADP 10 μmol/L: 54.8%, 52.1%, 50.4%, 49.7% maximal aggregation; ADP 15 μmol/L: 57.5%, 56.2%, 55.0%, 56.0% maximal aggregation; ADP 20 μmol/L: 63.3%, 66.2%, 64.0%, 64.2% maximal aggregation, for placebo-control-, clopidogrel-, ticagrelor-, and ticagrelor+8SPT-administered animals, re-spectively). The degree of platelet inhibition induced by clopidogrel and ticagrelor (±8SPT) throughout the experimental period on challenge with ADP is shown in Figure 1 . In comparison with placebo, clopidogrel and ticagrelor exerted a high and consistent inhibitory effect on platelet function at MI (degree of inhibition of platelet aggregation of control: 5.6%, 0.0%, 8.4%; clopidogrel: 60.0%, 71.9%, 68.2%; ticagrelor: 56.2%, 60.5%, 62.2%; ticagrelor+8SPT: 53.5%, 54.5%, 52.0%, for 10, 15, and 20 μmol/L ADP, respectively). This inhibitory effect persisted up to 24 hours post-MI (time of CMR analysis). 8SPT administration did not influence the high platelet inhibitory effect already exerted by a loading dose of ticagrelor. Both clopidogrel and ticagrelor treatment resulted in an increased bleeding time in comparison with placebo. Yet, despite a similar degree of platelet inhibition, clopidogrel resulted in a bleeding time almost twice as long as that seen with ticagrelor±8SPT (P<0.001; Figure 1D ), an effect already detected prior-MI. Neither clopidogrel nor ticagrelor altered any hematologic parameter (onlineonly Data Supplement Table III ). ticagrelor reduces cardiac Damage to a larger extent than clopidogrel: cMr analysis
The CMR data 24 hours post-MI is presented in Table. Compared with placebo-control, clopidogrel and ticagrelor treatment resulted in a significantly smaller infarct size in terms of both absolute infarct mass and percentage of affected LV myocardium (22.8 g LV, 15.7 g LV, and 12.0 g LV, respectively; Table) . However, ticagrelor administration reduced infarct size to a significantly greater extent than clopidogrel (further 3.7 g LV; 23.5% relative reduction; P=0.0026). The same pattern was observed in serum troponin-I levels at 24 hours post-MI (Table; P=0.0021 versus clopidogrel). In fact, a direct correlation was observed between infarct mass (assessed by CMR) and troponin-I levels (lineal correlation coefficient r=0.98; P<0.001). The extent of edema was increased 24 hours post-MI and showed a transmural distribution in all animals. Although edema volume did not differ between placebo and clopidogrel (23.4 g versus 21.6 g LV; P=0.33), it was found to be significantly reduced in ticagrelor-treated animals by 5.3 g LV (24.5% relative reduction; P=0.004 versus placebocontrol and clopidogrel; Table) . It is interesting to note that administration of 8SPT reversed the reduction in infarct size and antiedema effects observed in ticagrelor-treated animals. As such, the amount of edema in 7 of 8 ticagrelortreated animals was below the median of the clopidogreland ticagrelor+8SPT-treated arms (Figure 2A) . Linear regression analysis demonstrated that the amount of edema was highly correlated (r=0.74; P<0.001) with infarct mass ( Figure 2B ). We also detected a good correlation (r=0.831; P<0.001) between infarct volume as assessed by histology (2,3,5-triphenyltetrazolium chloride staining) and the CMR-assessed infarct mass, although some shrinkage always occurs in the postmortem tissues ( Figure 3 ).
In comparison with placebo, both clopidogrel-and ticagrelor-treated animals showed similar 10% relative improvement of LVEF (4% absolute improvement; P=0.01) and similar 21% relative reduction of left ventricular enddiastolic volume and left ventricular end-systolic volume (P=0.04) 24 hours post-MI (Table) .
ticagrelor reduces aquaporin-4 expression and activates aMPK signaling in the ischemic Myocardium Ticagrelor treatment was associated with a significant reduction in aquaporin-4 gene ( Figure 4A ) and protein ( Figure 4B ) expression in the ischemic myocardium 24 hours post-MI in comparison with placebo-control and clopidogrel reaching levels similar to those observed in the remote myocardium. Administration of 8SPT abolished ticagrelor effects on aquaporin-4 expression. To identify cells expressing aquaporin-4, isolated cell cultures were established. Aquaporin-4 was not expressed in isolated fibroblasts nor in endothelial cells (porcine aortic endothelial cells), but it was highly expressed in HL-1 cardiomyocytes (online-only Data Supplement Figure IV) .
As per AMPK, we observed that ticagrelor treatment induced activation of the AMPK-signaling pathway in the ischemic myocardium ( Figure 5A ) with the consequent activation and enhanced protein expression of its downstream effectors eNOS ( Figure 5B ) and CD36 ( Figure 5C as for AMPK expression in the different animal groups and cardiac regions ( Figure 5A ).
ticagrelor enhances Myocardial cox2 expression and activity and 6-Keto-prostaglandin F1α release
Ticagrelor was associated with higher Cox2 activity (Figure 6A ) and 6-keto-prostaglandin F1α levels (the stable metabolite of prostacyclin; Figure 6B ) in comparison with clopidogrel and placebo-control animals. Cox2 activity was barely detectable in the myocardium of the placebo-control group.
DiscUssiOn
Although the clinical benefit of P2Y 12 inhibitors in STEMI patients undergoing coronary reperfusion therapy has always been attributed to their antithrombotic action, experimental and clinical reports have suggested that some of these agents might reduce infarct size. 15, 16 In the present study, we found, in a preclinical animal model and by CMR, that ticagrelor and clopidogrel enhance myocardial viability in comparison with placebo-con-trol animals 24 hours post-MI. Yet, and most interesting, we provide evidence that ticagrelor limits cardiac injury (necrosis and edema) to a greater extent than clopidogrel when dosed to a similar degree of platelet P2Y 12 inhibition. The P2Y 12 -independent ticagrelor-related cardioprotective Chronic treatment with ticagrelor has been demonstrated to diminish the size of infarction in comparison with clopidogrel via an adenosine-dependent mechanism in a rat model of transient coronary occlusion. 16 The same research group using the same model has also shown that acute treatment with ticagrelor just before reperfusion reduces infarct size and that this translates into an improved heart function 4 weeks later. 23 However, in contrast to swine, translation of results in rodents is highly limited because of fundamental differences in heart anatomophysiology. 24 In fact, the ESC-Working Group Cellular Biology of the Heart Position Paper highlighted that studies in large animal models is an obligatory step before initiating human trials in cardioprotection. 25 Moreover, the ability to perform high-resolution CMR allows us to more accurately depict the protective effect of ticagrelor on cardiac damage beyond tissue necrosis, and provide data on edema, microvascular obstruction (no-reflow), and left ventricular contractibility and volumes, parameters of key importance for further clinical translatability.
Myocardial edema, a pathological consequence mainly related to ischemia and further reperfusion, has been shown to contribute to cell death, 26 yet the mechanisms and players of edema formation are only partially under-stood. 19 We observe that ticagrelor-administered animals modulate critical components involved in both intracellular and extracellular myocardial edema formation such as aquaporin-4 and AMPK, respectively, via adenosine-related mechanisms. First, we detected that ticagrelor-administered animals show a marked attenuation in both aquaporin-4 mRNA and protein expression, an effect reversed on 8SPT administration. Aquaporin-4, a transmembrane channel critically involved in cellular water balance, has been demonstrated to be primarily responsible for the development of cerebral edema. 20 However, although present in human cardiomyocytes, aquaporin-4 regulation and function remain largely unknown. 27 A recent study demonstrated that cardiomyocyte aquaporin-4 activity was enhanced after ischemia, and its upregulation was associated with increased myocyte swelling and size of infarction. 28 In fact, aquaporin-4 expression has been shown to coincide with myocardial edema and cardiac dysfunction in a mouse model of MI, an effect not observed by other cardiac aquaporins. 29 Most important, recent studies in mice have demonstrated that adenosine signaling regulates aquaporin-4 expression 30 and that aquaporin-4 is found significantly reduced in ENT-1 null mice versus their wild-type counterparts. 31 Altogether, these observations allow us to propose a link between ticagrelor, subsequent ENT-1 blockade, adenosine increase and signaling, and eventual aquaporine-4 diminishment in the infarcted heart.
We also report that ticagrelor administration is associated with an enhanced activation of the AMPK-signaling pathway in the ischemic cardiac region and consequent activation/increase in eNOS and CD36 downstream effectors. Besides being a key sensor of energy status, AMPK has recently been shown to preserve endothelial barrier permeability preventing ventricle edema formation on cardiac sepsis. 21 We therefore speculate that the enhanced AMPK-signaling activation observed in ticagrelortreated animals may have attenuated vascular dysfunction because of MI induction limiting the passage of plasma into the interstitial compartment of the ischemic damaged myocardium. 32 It is worth mentioning that several recent studies have proposed that activated AMPK protects against sepsis-induced organ damage and inflammation. 33 These observations may also explain in part the post hoc analysis of the PLATO trial showing the ticagrelor-associated reduction in sepsis mortality in ACS patients. 34 AMPK is mainly activated on extracellular increase in adenosine levels, and a recent study has shown impaired AMPK phosphorylation in adenosine A2B receptor-deficient mice. 35 A study in patients with ACS has revealed that adenosine plasma concentrations are significantly higher in ticagrelor-treated than in clopidogrel-treated patients, likely enhancing adenosine biological effects on the cardiovascular system. 36 Moreover, adenosine has been attributed to afford cardioprotection in ischemic conditioning (pre, post, and remote) by interacting with adenosine receptors, 37 which, in turn, has been shown to reduce edema formation in humans. 38 So far, clinical studies with adenosine in STEMI patients have yielded mixed results. 24 In a post hoc subgroup analysis of the AMISTAD-II trial (Acute Myocardial Infarction Study of Adenosine) a significant reduction in infarct size was reported in the high-dose adenosine subgroup reperfused within 3 hours. 39 However, no evidence of adenosinecardioprotective effects was observed in larger clinical trials by CMR. 40 Adenosine and adenosine analogues have been shown in animal models to mimic ischemic preconditioning and to potentially prevent lethal myocardial reperfusion injury after an ischemic episode. 37 However, systemic infusion of exogenous adenosine, with a half-life counted in seconds, may be quite different from a continuous enhancement of local endogenous adenosine release at sites of ischemia or tissue injury as provided by ticagrelor. In fact, the REDUCE-MVI trial (Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction) 41 is currently testing whether ticagrelor, via ENT-1/adenosine-mediated mechanisms, improves microvascular function in revascularized STEMI patients.
Adenosine-receptor activation can also induce eNOS phosphorylation 42 which, in turn, has been shown to be essential for downstream upregulation of Cox2 activity and consequent reduction in cardiac damage. Ticagrelor increases Cox2 activity and 6-keto-prostaglandin F1α release in the damaged myocardium via adenosine receptor-related mechanisms. 16, 43 It is important to notice that we did not treat pigs with aspirin to investigate the sole effect of P2Y 12 inhibition in the infarcted myocardium. Indeed, during primary percutaneous coronary intervention, ticagrelor-related Cox2/prostaglandin I2 cardioprotective effects may be acutely abolished on aspirin loading. 44 Moreover, ticagrelor has shown a reduced efficacy in North American patients where higher maintenance doses of aspirin (>300 mg) are more widely prescribed. 45 However, ticagrelor may overcome such aspirin-loading dose effects and resume its Cox2-related cardioprotecitve effects when daily low-dose aspirin therapy is given. Indeed, low doses of aspirin do not affect Cox2 activity, which, in concert with ticagrelor-derived adenosine-dependent benefits, may contribute to explaining ticagrelor benefits reported long after MI in PEGASUS patients (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). 46 As to cardiac performance, LVEF was significantly improved in both antiplatelet-treated arms in comparison with the placebo-control arm, yet no differences were observed between the actively treated groups despite lower myocardial damage in the ticagrelor-treated animals. To ascertain whether the acute cardioprotective benefit exerted by ticagrelor over clopidogrel within 24 hours of infarction translate into an attenuated cardiacremodeling process and improved cardiac output, longterm follow-up studies are required. This is particularly in-teresting because a reduction in edema has been shown to improve cardiac function over time. 47 Bleeding time was also markedly shorter in ticagrelortreated animals versus clopidogrel-treated pigs. Bleeding time, assessed by a small incision in the ear skin, mainly screens for defects of primary hemostasis and coagulation. We did not detect differences in conventional coagulation function testing or clot dynamics among all animals, allowing us to exclude the interference of ticagrelor with the intrinsic and extrinsic coagulation cascade and fibrinogen. The data in terms of separation of bleeding and antiplatelet/antithrombotic effect in this pig model nicely confirms prior published data generated in rats and dogs. 48 The reason for this is currently unclear but is likely related to irreversible (thienopyridines) versus reversible (ticagrelor) binding mode of action to the P2Y 12 receptor. Comparing the clinical data in PLATO 3 and TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension), 4 one can argue that the animal data translate also into a wider separation between efficacy and bleeding in patients, because both clinical studies tested a similar increased platelet inhibition versus clopidogrel, but prasugrel appeared to induce more severe bleeding. Studies are currently underway to determine how ticagrelor modulates the formation of the plug to achieve an earlier hemostasis.
Fernández-Jiménez et al 49 recently performed a CMR study in swine to determine the dynamics of edema formation after 40 minutes of coronary artery occlusion followed by reperfusion. The authors detected a rapid and marked increase in tissue water at 2 hours of reperfusion that was largely resolved at 24 hours, but then a second increase in water content appeared. In contrast, we detect edema 24 hours after MI. This discrepancy is likely explained by the differences between the ischemic insults. Longer ischemic periods have been shown to result in larger infarcts and subsequently enhance myocyte damage and edema formation. 50 Our study has some limitations. First, we did not perform the study in all the animals reported within the sample size calculation (n=10). Because we adhere to the 3R (replacement, reduction, and refinement) code of the European Union in animal use and euthanization, we felt that it was unethical to include more animals to corroborate the already statistically significant results reached with a lower number. Second, in the present study, we performed CMR analysis at 24 hours; therefore, we cannot draw conclusions regarding the potential benefits of ticagrelor in the longer term. However, longer-term studies are warranted. Third, our mechanistic study has not included comorbidities found in most STEMI patients. We cannot ascertain from our present studies whether reduction of edema and cardioprotection are attributable to an effect of ticagrelor on aquaporin-4 expression and AMPK signaling or if these latter are modulated because ticagrelor reduced edema through a different mechanism. Further studies are needed to elucidate whether the association is a cause or an effect.
cOnclUsiOns
We have shown the increased capability of ticagrelor to reduce MI-induced cardiac damage (edema and necrosis) over clopidogrel by CMR analyses in a preclinical animal model. Moreover, we demonstrate that ticagrelor antiedema protective effects are mainly mediated through adenosine and are associated with a reduction in aquaporin-4 levels and the activation of AMPK signaling in the ischemic myocardium. 
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